Antimicrobial Resistance Market By Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), By Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, Others), By Indication (Complicated Urinary Tract Infections (cUTI), Blood stream infections, Acute bacterial skin and skin structure infections (ABSSSI), Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), Community acquired pneumonia (CAP), Others), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Antimicrobial Resistance Market

The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sector –  

Antimicrobial resistance (AMR) is referred to the resistance developed by the microorganisms against the antibiotics over time. Antibiotics are often prescribed on a large scale for treatment of various bacterial infections and sometimes may be misused in treatment of viral infections. It has proved to be a global threat to the healthcare sector and is anticipated to grow at an alarming rate. Such misuse of antibiotics is the major factor that causes antimicrobial resistance among microorganisms. Thus, there is an urgent need for innovative antibiotics that are effective against these resistant bacteria, which propels the growth of the antimicrobial resistance market.   

Key factors driving the growth of the antimicrobial resistance market are overuse and misuse of antibiotics, rise in prevalence of antimicrobial resistance bacterial infections and growth in burden of antimicrobial resistance. The burden of antimicrobial resistance is rising at an alarming rate which leads to severe negative effects on the healthcare systems around the globe. 

In addition, according to the National Infection & Death Estimates for Antimicrobial Resistance, in the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.  Such huge burden of antimicrobial resistance leads to high treatment cost, increased mortality and morbidity, limited treatment options, and increased hospital stays. Also, the available treatment becomes ineffective which demands new and novel antibiotics that can overcome the AMR burden and propels the market growth.  

Furthermore, the antimicrobial resistance market is expected to experience significant growth opportunities in developing regions over the next few years. The developing regions are working towards improving their healthcare infrastructure for which they need to set up and expand medical facilities, such as hospitals, clinics and outpatient care centers. This growth in medical facilities creates a need for novel antimicrobials, which are needed for effective patient care. This boosts market growth. 

In addition, there is a surge in research and development activities to develop novel antibiotics medications which can be used in the treatment of resistant bacteria are anticipated to contribute to the market growth during the forecast period.  

The antimicrobial resistance market is segmented on the antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. Based on on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others.  

On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

 The key players profiled in the study include Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc. The players in the market have been actively engaged in the adoption of various strategies such as collaboration, funding, acquisition, product approval, product upgrade/development, agreement and product launch to remain competitive and gain an advantage over the competitors in the market.  

For instance, in July 2020, Nabriva Therapeutics plc announced that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults. 

Key Market Insights 

By drug class, the combination therapies segment was the highest revenue contributor to the market whereas the others segment is anticipated to be the fastest growing segment during the forecast period.   

By pathogen, the Escherichia coli segment dominated the global market whereas the Klebsiella pneumoniae segment is expected to be the fastest-growing segment during the forecast period. 

By indication, the complicated urinary tract infections (cUTI) segment dominated the market in 2022, whereas the hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP & VABP) segment is anticipated to grow at a fastest rate during the forecast period.  

By mechanism of action, the cell wall synthesis inhibitors segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period.  

Based on region, North America garnered the largest revenue share in 2022, and Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

Antimicrobial resistance (AMR), also known as drug resistance is the resistance developed by the bacteria, viruses, fungi, and parasites to the available antimicrobial drugs over a period. It is a comprehensive concept and often encompasses resistance to antibacterial, antiviral, antiparasitic, and antifungal drugs. The microorganisms which become resistant to most of the antimicrobials are often referred to as superbugs. Few examples of superbugs include MRSA (methicillin-resistant staphylococcus aureus), Clostridium difficile (C. diff), and the bacteria that cause multi-drug-resistant tuberculosis. 

Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial. 

Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.

In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance. 

Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.

On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent. 

However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period. 

The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.

On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

Key Market Segments

○ Merck & Co., Inc

Scope of Antimicrobial Resistance Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Overuse and misuse of antibiotics

3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections

3.4.1.3. Growth in burden of antimicrobial resistance

3.4.2. Restraints

3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance

3.4.3. Opportunities

3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally

4.1. Overview

4.1.1. Market size and forecast

4.2. Combination therapies

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Tetracyclines

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Cephalosporins

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Glycopeptides and Lipoglycopeptides

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Oxazolidinones

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities

4.7.2. Market size and forecast, by region

4.7.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Escherichia coli

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Klebsiella pneumoniae

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Pseudomonas aeruginosa

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Staphylococcus aureus

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Enterococcus Spp

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

5.7. Others

5.7.1. Key market trends, growth factors and opportunities

5.7.2. Market size and forecast, by region

5.7.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Complicated Urinary Tract Infections (cUTI)

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Blood stream infections

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Acute bacterial skin and skin structure infections (ABSSSI)

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)

6.5.1. Key market trends, growth factors and opportunities

6.5.2. Market size and forecast, by region

6.5.3. Market share analysis by country

6.6. Community acquired pneumonia (CAP)

6.6.1. Key market trends, growth factors and opportunities

6.6.2. Market size and forecast, by region

6.6.3. Market share analysis by country

6.7. Others

6.7.1. Key market trends, growth factors and opportunities

6.7.2. Market size and forecast, by region

6.7.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Protein Synthesis Inhibitors

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Cell Wall Synthesis Inhibitors

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Others

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Drug Class

8.2.3. Market size and forecast, by Pathogen

8.2.4. Market size and forecast, by Indication

8.2.5. Market size and forecast, by Mechanism of Action

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Drug Class

8.2.6.1.2. Market size and forecast, by Pathogen

8.2.6.1.3. Market size and forecast, by Indication

8.2.6.1.4. Market size and forecast, by Mechanism of Action

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Drug Class

8.2.6.2.2. Market size and forecast, by Pathogen

8.2.6.2.3. Market size and forecast, by Indication

8.2.6.2.4. Market size and forecast, by Mechanism of Action

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Drug Class

8.2.6.3.2. Market size and forecast, by Pathogen

8.2.6.3.3. Market size and forecast, by Indication

8.2.6.3.4. Market size and forecast, by Mechanism of Action

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Drug Class

8.3.3. Market size and forecast, by Pathogen

8.3.4. Market size and forecast, by Indication

8.3.5. Market size and forecast, by Mechanism of Action

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Drug Class

8.3.6.1.2. Market size and forecast, by Pathogen

8.3.6.1.3. Market size and forecast, by Indication

8.3.6.1.4. Market size and forecast, by Mechanism of Action

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Drug Class

8.3.6.2.2. Market size and forecast, by Pathogen

8.3.6.2.3. Market size and forecast, by Indication

8.3.6.2.4. Market size and forecast, by Mechanism of Action

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Drug Class

8.3.6.3.2. Market size and forecast, by Pathogen

8.3.6.3.3. Market size and forecast, by Indication

8.3.6.3.4. Market size and forecast, by Mechanism of Action

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Drug Class

8.3.6.4.2. Market size and forecast, by Pathogen

8.3.6.4.3. Market size and forecast, by Indication

8.3.6.4.4. Market size and forecast, by Mechanism of Action

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Drug Class

8.3.6.5.2. Market size and forecast, by Pathogen

8.3.6.5.3. Market size and forecast, by Indication

8.3.6.5.4. Market size and forecast, by Mechanism of Action

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Drug Class

8.3.6.6.2. Market size and forecast, by Pathogen

8.3.6.6.3. Market size and forecast, by Indication

8.3.6.6.4. Market size and forecast, by Mechanism of Action

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Drug Class

8.4.3. Market size and forecast, by Pathogen

8.4.4. Market size and forecast, by Indication

8.4.5. Market size and forecast, by Mechanism of Action

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Drug Class

8.4.6.1.2. Market size and forecast, by Pathogen

8.4.6.1.3. Market size and forecast, by Indication

8.4.6.1.4. Market size and forecast, by Mechanism of Action

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Drug Class

8.4.6.2.2. Market size and forecast, by Pathogen

8.4.6.2.3. Market size and forecast, by Indication

8.4.6.2.4. Market size and forecast, by Mechanism of Action

8.4.6.3. India

8.4.6.3.1. Market size and forecast, by Drug Class

8.4.6.3.2. Market size and forecast, by Pathogen

8.4.6.3.3. Market size and forecast, by Indication

8.4.6.3.4. Market size and forecast, by Mechanism of Action

8.4.6.4. Australia

8.4.6.4.1. Market size and forecast, by Drug Class

8.4.6.4.2. Market size and forecast, by Pathogen

8.4.6.4.3. Market size and forecast, by Indication

8.4.6.4.4. Market size and forecast, by Mechanism of Action

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Drug Class

8.4.6.5.2. Market size and forecast, by Pathogen

8.4.6.5.3. Market size and forecast, by Indication

8.4.6.5.4. Market size and forecast, by Mechanism of Action

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Drug Class

8.4.6.6.2. Market size and forecast, by Pathogen

8.4.6.6.3. Market size and forecast, by Indication

8.4.6.6.4. Market size and forecast, by Mechanism of Action

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Drug Class

8.5.3. Market size and forecast, by Pathogen

8.5.4. Market size and forecast, by Indication

8.5.5. Market size and forecast, by Mechanism of Action

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Drug Class

8.5.6.1.2. Market size and forecast, by Pathogen

8.5.6.1.3. Market size and forecast, by Indication

8.5.6.1.4. Market size and forecast, by Mechanism of Action

8.5.6.2. Saudi Arabia

8.5.6.2.1. Market size and forecast, by Drug Class

8.5.6.2.2. Market size and forecast, by Pathogen

8.5.6.2.3. Market size and forecast, by Indication

8.5.6.2.4. Market size and forecast, by Mechanism of Action

8.5.6.3. South Africa

8.5.6.3.1. Market size and forecast, by Drug Class

8.5.6.3.2. Market size and forecast, by Pathogen

8.5.6.3.3. Market size and forecast, by Indication

8.5.6.3.4. Market size and forecast, by Mechanism of Action

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Drug Class

8.5.6.4.2. Market size and forecast, by Pathogen

8.5.6.4.3. Market size and forecast, by Indication

8.5.6.4.4. Market size and forecast, by Mechanism of Action

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Top player positioning, 2022

10.1. Alkem Laboratories Ltd.

10.1.1. Company overview

10.1.2. Key Executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.1.7. Key strategic moves and developments

10.2. Pfizer Inc.

10.2.1. Company overview

10.2.2. Key Executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.2.7. Key strategic moves and developments

10.3. Acurx Pharmaceuticals, Inc.

10.3.1. Company overview

10.3.2. Key Executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.4. Basilea Pharmaceutica Ltd

10.4.1. Company overview

10.4.2. Key Executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Business performance

10.5. Cumberland Pharmaceuticals

10.5.1. Company overview

10.5.2. Key Executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.5.7. Key strategic moves and developments

10.6. Wockhardt Limited.

10.6.1. Company overview

10.6.2. Key Executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Business performance

10.7. Paratek Pharmaceuticals Inc

10.7.1. Company overview

10.7.2. Key Executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.7.6. Business performance

10.8. Nabriva Therapeutics plc

10.8.1. Company overview

10.8.2. Key Executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.8.6. Business performance

10.8.7. Key strategic moves and developments

10.9. Innoviva, Inc

10.9.1. Company overview

10.9.2. Key Executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.10. Merck & Co., Inc.

10.10.1. Company overview

10.10.2. Key Executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfolio

10.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 02. ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY REGION, 2022-2032 ($MILLION)

TABLE 04. ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY REGION, 2022-2032 ($MILLION)

TABLE 06. ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY REGION, 2022-2032 ($MILLION)

TABLE 07. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 09. ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY REGION, 2022-2032 ($MILLION)

TABLE 10. ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2022-2032 ($MILLION)

TABLE 11. ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY REGION, 2022-2032 ($MILLION)

TABLE 12. ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY REGION, 2022-2032 ($MILLION)

TABLE 14. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 16. ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2022-2032 ($MILLION)

TABLE 17. ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY REGION, 2022-2032 ($MILLION)

TABLE 18. ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2022-2032 ($MILLION)

TABLE 19. ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY REGION, 2022-2032 ($MILLION)

TABLE 20. ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY REGION, 2022-2032 ($MILLION)

TABLE 21. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 23. ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)

TABLE 24. ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)

TABLE 25. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 26. ANTIMICROBIAL RESISTANCE MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 27. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 28. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 29. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 30. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 31. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 32. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 33. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 34. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 35. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 36. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 38. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 39. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 40. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 41. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 42. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 43. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 44. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 45. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 46. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 47. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 48. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 49. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 50. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 51. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 52. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 53. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 54. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 55. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 56. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 57. UK ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 58. UK ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 59. UK ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 60. UK ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 61. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 62. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 63. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 64. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 65. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 66. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 67. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 68. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 69. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 70. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 71. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 72. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 73. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 74. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 75. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 76. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 77. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 78. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 79. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 80. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 81. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 82. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 83. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 84. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 85. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 86. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 87. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 88. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 89. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 90. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 91. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 92. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 93. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 94. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 95. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 96. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 97. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 98. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 99. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 100. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 101. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 102. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 103. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 104. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 105. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 106. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 107. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 108. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 109. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 110. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 111. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 112. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 113. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 114. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 115. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 116. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 117. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 118. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 119. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 120. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)

TABLE 121. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 122. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)

TABLE 123. ALKEM LABORATORIES LTD.: KEY EXECUTIVES

TABLE 124. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 125. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS

TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 127. ALKEM LABORATORIES LTD.: KEY STRATERGIES

TABLE 128. PFIZER INC.: KEY EXECUTIVES

TABLE 129. PFIZER INC.: COMPANY SNAPSHOT

TABLE 130. PFIZER INC.: PRODUCT SEGMENTS

TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 132. PFIZER INC.: KEY STRATERGIES

TABLE 133. ACURX PHARMACEUTICALS, INC.: KEY EXECUTIVES

TABLE 134. ACURX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 135. ACURX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS

TABLE 136. ACURX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 137. BASILEA PHARMACEUTICA LTD: KEY EXECUTIVES

TABLE 138. BASILEA PHARMACEUTICA LTD: COMPANY SNAPSHOT

TABLE 139. BASILEA PHARMACEUTICA LTD: PRODUCT SEGMENTS

TABLE 140. BASILEA PHARMACEUTICA LTD: PRODUCT PORTFOLIO

TABLE 141. CUMBERLAND PHARMACEUTICALS: KEY EXECUTIVES

TABLE 142. CUMBERLAND PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 143. CUMBERLAND PHARMACEUTICALS: PRODUCT SEGMENTS

TABLE 144. CUMBERLAND PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 145. CUMBERLAND PHARMACEUTICALS: KEY STRATERGIES

TABLE 146. WOCKHARDT LIMITED.: KEY EXECUTIVES

TABLE 147. WOCKHARDT LIMITED.: COMPANY SNAPSHOT

TABLE 148. WOCKHARDT LIMITED.: PRODUCT SEGMENTS

TABLE 149. WOCKHARDT LIMITED.: PRODUCT PORTFOLIO

TABLE 150. PARATEK PHARMACEUTICALS INC: KEY EXECUTIVES

TABLE 151. PARATEK PHARMACEUTICALS INC: COMPANY SNAPSHOT

TABLE 152. PARATEK PHARMACEUTICALS INC: PRODUCT SEGMENTS

TABLE 153. PARATEK PHARMACEUTICALS INC: PRODUCT PORTFOLIO

TABLE 154. NABRIVA THERAPEUTICS PLC: KEY EXECUTIVES

TABLE 155. NABRIVA THERAPEUTICS PLC: COMPANY SNAPSHOT

TABLE 156. NABRIVA THERAPEUTICS PLC: PRODUCT SEGMENTS

TABLE 157. NABRIVA THERAPEUTICS PLC: PRODUCT PORTFOLIO

TABLE 158. NABRIVA THERAPEUTICS PLC: KEY STRATERGIES

TABLE 159. INNOVIVA, INC: KEY EXECUTIVES

TABLE 160. INNOVIVA, INC: COMPANY SNAPSHOT

TABLE 161. INNOVIVA, INC: PRODUCT SEGMENTS

TABLE 162. INNOVIVA, INC: PRODUCT PORTFOLIO

TABLE 163. MERCK & CO., INC.: KEY EXECUTIVES

TABLE 164. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 165. MERCK & CO., INC.: PRODUCT SEGMENTS

TABLE 166. MERCK & CO., INC.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. ANTIMICROBIAL RESISTANCE MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF ANTIMICROBIAL RESISTANCE MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN ANTIMICROBIAL RESISTANCE MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW INTENSITY OF RIVALRY

FIGURE 08. LOW BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL ANTIMICROBIAL RESISTANCE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022 AND 2032(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY COUNTRY 2022 AND 2032(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY COUNTRY 2022 AND 2032(%)

FIGURE 28. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY COUNTRY 2022 AND 2032(%)

FIGURE 29. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY COUNTRY 2022 AND 2032(%)

FIGURE 30. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 31. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022 AND 2032(%)

FIGURE 32. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY COUNTRY 2022 AND 2032(%)

FIGURE 33. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY COUNTRY 2022 AND 2032(%)

FIGURE 34. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 35. ANTIMICROBIAL RESISTANCE MARKET BY REGION, 2022 AND 2032(%)

FIGURE 36. U.S. ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 38. MEXICO ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 39. GERMANY ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 40. FRANCE ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 41. UK ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 42. ITALY ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 43. SPAIN ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 44. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 45. JAPAN ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 46. CHINA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 47. INDIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 48. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 49. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 50. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 51. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 52. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 53. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 54. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)

FIGURE 55. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 58. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 59. COMPETITIVE DASHBOARD

FIGURE 60. COMPETITIVE HEATMAP: ANTIMICROBIAL RESISTANCE MARKET

FIGURE 61. TOP PLAYER POSITIONING, 2022

FIGURE 62. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 65. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 66. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 67. BASILEA PHARMACEUTICA LTD: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 68. BASILEA PHARMACEUTICA LTD: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 69. CUMBERLAND PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 70. WOCKHARDT LIMITED.: NET REVENUE, 2021-2023 ($MILLION)

FIGURE 71. WOCKHARDT LIMITED.: REVENUE SHARE BY REGION, 2023 (%)

FIGURE 72. PARATEK PHARMACEUTICALS INC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 73. NABRIVA THERAPEUTICS PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 74. INNOVIVA, INC: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 75. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 76. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 77. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%